About this source
- Kind
- Research
- Design
- Human clinical trial, RCT
- Population
- 3,417 adults with overweight/obesity and 1 or more comorbidity, without type 2 diabetes
- Sample size
- 3417
- Primary or secondary
- primary
- Peer review
- peer reviewed
- Retraction status
- None known
- Date checked
- 14 August 2026
Limitations
Sponsor-funded (Novo Nordisk); studies the fixed-dose combination as the primary comparison, not cagrilintide as a standalone agent.
Cited in
Spotted an error? Report a problem with this page. We correct the record and log every change on What's changed.